OrsoBio

OrsoBio is a clinical-stage biopharmaceutical company striving to advance first-in-class therapies that aim to restore energy homeostasis. With a focus on severe metabolic disorders like type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis, OrsoBio currently has four programs in clinical and preclinical development. These programs feature first-in-class compounds targeting central pathways in energy metabolism. Founded in 2021 and headquartered in the United States, the company recently secured a significant investment of $60.00M in a Series A funding round on 07 November 2023. Notably, the investors in this round included Longitude Capital, Eli Lilly, Enavate Sciences, Samsara BioCapital, and NuevaBio. The company's dedication to addressing critical gaps in metabolic disorder treatment through innovative therapies positions OrsoBio as a promising player in the biopharma, biotechnology, and healthcare industries.